Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Ashton

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Biochemical Pharmacology|August 10, 2025
ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms raceJ C Ashton
Neuroscience|January 3, 2012
Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injuryP W Brownjohn, J C Ashton
Canadian Anaesthetists' Society Journal|May 1, 1983
Siemens PCO2 Gas AnalyserG L Dunn, D H Morison, J C Ashton
Scientific Reports|June 20, 2023
Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitorsM A Berry, A R Bland, J C Ashton
Neuroscience Letters|April 12, 2014
The cannabinoid CB2 receptor agonist GW405833 does not ameliorate brain damage induced by hypoxia-ischemia in ratsJ R Rivers-Auty, P F Smith, J C Ashton
Scientific Reports|December 13, 2019
Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancerN Shrestha, M Nimick, P Dass, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 15, 2020
Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung CancerN Shrestha, A R Bland, R L Bower, et al.
Biochemical Pharmacology|November 23, 2020
The effect of metformin in EML<sub>4</sub>-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent modelsA R Bland, N Shrestha, R L Bower, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Biochemical Pharmacology|August 10, 2025
ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms raceJ C Ashton
Neuroscience|January 3, 2012
Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injuryP W Brownjohn, J C Ashton
Canadian Anaesthetists' Society Journal|May 1, 1983
Siemens PCO2 Gas AnalyserG L Dunn, D H Morison, J C Ashton
Scientific Reports|June 20, 2023
Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitorsM A Berry, A R Bland, J C Ashton
Neuroscience Letters|April 12, 2014
The cannabinoid CB2 receptor agonist GW405833 does not ameliorate brain damage induced by hypoxia-ischemia in ratsJ R Rivers-Auty, P F Smith, J C Ashton
Scientific Reports|December 13, 2019
Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancerN Shrestha, M Nimick, P Dass, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 15, 2020
Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung CancerN Shrestha, A R Bland, R L Bower, et al.
Biochemical Pharmacology|November 23, 2020
The effect of metformin in EML<sub>4</sub>-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent modelsA R Bland, N Shrestha, R L Bower, et al.
Pageof 1